Chronic Kidney Disease News

Brief dialysis may lead to better outcomes for patients with AKI on outpatient hemodialysis, according to recently published data from researchers at the University of California, San Francisco.

Patients who receive hemodialysis prior to their first kidney transplant may be more likely to develop atrial fibrillation compared with patients who have peritoneal dialysis, according to recent data.

A structured exercise intervention slowed kidney function decline in older adults and higher activity was associated with overall health improvements, research shows.

Women with chronic kidney disease commonly experience abnormal menstruation and infertility, but knowledge and discussion around these issues are lacking, according to a study of women’s reproductive health in CKD.

An interim analysis of outcomes from a phase 3 trial evaluating narsoplimab for the treatment of immunoglobulin A nephropathy showed the reduction in proteinuria from baseline did not reach statistical significance compared with placebo.

The FDA has approved Xphozah to reduce serum phosphorus in adults with chronic kidney disease on dialysis as an add-on therapy in patients who have an inadequate response to phosphate binders, according to a press release from Ardelyx Inc.

Nearly one-third of dialysis clinics completed training on care coordination and care transitions when it was offered, according to a study published in Kidney Medicine.

In patients with chronic kidney disease, high diastolic blood pressure did not increase risk for adverse kidney or cardiovascular events if systolic BP is under control, according to a study published in Kidney Medicine.

Open communication with health care providers may help improve dietary adherence in patients on hemodialysis and peritoneal dialysis, according to a recently published study.

Novo Nordisk has ended a clinical trial evaluating the impact of semaglutide on kidney function after the results from an interim analysis met certain pre-specified criteria, according to a company press release. To protect the integrity of the trial, Novo Nordisk will remain blinded to the results until the trial is completed, likely during the first half of 2024, according to the release.